List of Oncolix patents | 5 results

Name	Description	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 8648046 Compositions and methods for visualizing and eliminating cancer stem cells	Patent 8648046 was granted and assigned to Oncolix on February, 2014 by the United States Patent and Trademark Office.	Oncolix	United States Patent and Trademark Office	8648046	February 11, 2014
‌ US Patent 8754035 Compositions and methods for visualizing and eliminating cancer stem cells	Patent 8754035 was granted and assigned to Oncolix on June, 2014 by the United States Patent and Trademark Office.	Oncolix	United States Patent and Trademark Office	8754035	June 17, 2014
‌ US Patent 8754031 Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway	Patent 8754031 was granted and assigned to Oncolix on June, 2014 by the United States Patent and Trademark Office.	Oncolix	United States Patent and Trademark Office	8754031	June 17, 2014
‌ US Patent 7632809 Multimeric ligands with enhanced stability	Patent 7632809 was granted and assigned to Oncolix on December, 2009 by the United States Patent and Trademark Office.	Oncolix	United States Patent and Trademark Office	7632809	December 15, 2009
‌ US Patent 8304381 Human prolactin antagonist-angiogenesis inhibitor fusion proteins	Patent 8304381 was granted and assigned to Oncolix on November, 2012 by the United States Patent and Trademark Office.	Oncolix	United States Patent and Trademark Office	8304381	November 6, 2012